ESPR Quote, Financials, Valuation and Earnings

Catalyst Pharmaceuticals, Inc. has a net margin of 36.71% compared to Esperion Therapeutics, Inc.'s net margin of 34.53%. Esperion Therapeutics, Inc.'s return on equity of -- beat Catalyst Pharmaceuticals, Inc.'s return on equity of 25.2%.

Esperion Therapeutics, Inc. has a consensus price target of $6.87, signalling upside risk potential of 178.08%. On the other hand Catalyst Pharmaceuticals, Inc. has an analysts' consensus of $34.00 which suggests that it could grow by 45.36%. Given that Esperion Therapeutics, Inc. has higher upside potential than Catalyst Pharmaceuticals, Inc., analysts believe Esperion Therapeutics, Inc. is more attractive than Catalyst Pharmaceuticals, Inc..

Esperion Therapeutics, Inc. has a beta of 1.107, which suggesting that the stock is 10.692% more volatile than S&P 500. In comparison Catalyst Pharmaceuticals, Inc. has a beta of 0.746, suggesting its less volatile than the S&P 500 by 25.388%.

Esperion Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Esperion Therapeutics, Inc. pays -- of its earnings as a dividend. Catalyst Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Esperion Therapeutics, Inc. quarterly revenues are $168.4M, which are larger than Catalyst Pharmaceuticals, Inc. quarterly revenues of $152.6M. Esperion Therapeutics, Inc.'s net income of $61.8M is higher than Catalyst Pharmaceuticals, Inc.'s net income of $52.7M. Notably, Esperion Therapeutics, Inc.'s price-to-earnings ratio is -- while Catalyst Pharmaceuticals, Inc.'s PE ratio is 13.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Esperion Therapeutics, Inc. is 1.35x versus 5.05x for Catalyst Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Harrow, Inc. has a net margin of 36.71% compared to Esperion Therapeutics, Inc.'s net margin of 7.44%. Esperion Therapeutics, Inc.'s return on equity of -- beat Harrow, Inc.'s return on equity of -9.4%.

Esperion Therapeutics, Inc. has a consensus price target of $6.87, signalling upside risk potential of 178.08%. On the other hand Harrow, Inc. has an analysts' consensus of $69.63 which suggests that it could grow by 95.8%. Given that Esperion Therapeutics, Inc. has higher upside potential than Harrow, Inc., analysts believe Esperion Therapeutics, Inc. is more attractive than Harrow, Inc..

Esperion Therapeutics, Inc. has a beta of 1.107, which suggesting that the stock is 10.692% more volatile than S&P 500. In comparison Harrow, Inc. has a beta of 0.050, suggesting its less volatile than the S&P 500 by 95.003%.

Esperion Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harrow, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Esperion Therapeutics, Inc. pays -- of its earnings as a dividend. Harrow, Inc. pays out -- of its earnings as a dividend.

Esperion Therapeutics, Inc. quarterly revenues are $168.4M, which are larger than Harrow, Inc. quarterly revenues of $89.1M. Esperion Therapeutics, Inc.'s net income of $61.8M is higher than Harrow, Inc.'s net income of $6.6M. Notably, Esperion Therapeutics, Inc.'s price-to-earnings ratio is -- while Harrow, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Esperion Therapeutics, Inc. is 1.35x versus 4.92x for Harrow, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Nektar Therapeutics has a net margin of 36.71% compared to Esperion Therapeutics, Inc.'s net margin of -301.29%. Esperion Therapeutics, Inc.'s return on equity of -- beat Nektar Therapeutics's return on equity of -327.67%.

Esperion Therapeutics, Inc. has a consensus price target of $6.87, signalling upside risk potential of 178.08%. On the other hand Nektar Therapeutics has an analysts' consensus of $129.86 which suggests that it could grow by 84.56%. Given that Esperion Therapeutics, Inc. has higher upside potential than Nektar Therapeutics, analysts believe Esperion Therapeutics, Inc. is more attractive than Nektar Therapeutics.

Esperion Therapeutics, Inc. has a beta of 1.107, which suggesting that the stock is 10.692% more volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 1.170, suggesting its more volatile than the S&P 500 by 16.958%.

Esperion Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Esperion Therapeutics, Inc. pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

Esperion Therapeutics, Inc. quarterly revenues are $168.4M, which are larger than Nektar Therapeutics quarterly revenues of $11.8M. Esperion Therapeutics, Inc.'s net income of $61.8M is higher than Nektar Therapeutics's net income of -$35.5M. Notably, Esperion Therapeutics, Inc.'s price-to-earnings ratio is -- while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Esperion Therapeutics, Inc. is 1.35x versus 72.55x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Rigel Pharmaceuticals, Inc. has a net margin of 36.71% compared to Esperion Therapeutics, Inc.'s net margin of 40.17%. Esperion Therapeutics, Inc.'s return on equity of -- beat Rigel Pharmaceuticals, Inc.'s return on equity of 299.43%.

Esperion Therapeutics, Inc. has a consensus price target of $6.87, signalling upside risk potential of 178.08%. On the other hand Rigel Pharmaceuticals, Inc. has an analysts' consensus of $51.20 which suggests that it could grow by 92.48%. Given that Esperion Therapeutics, Inc. has higher upside potential than Rigel Pharmaceuticals, Inc., analysts believe Esperion Therapeutics, Inc. is more attractive than Rigel Pharmaceuticals, Inc..

Esperion Therapeutics, Inc. has a beta of 1.107, which suggesting that the stock is 10.692% more volatile than S&P 500. In comparison Rigel Pharmaceuticals, Inc. has a beta of 1.102, suggesting its more volatile than the S&P 500 by 10.219%.

Esperion Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rigel Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Esperion Therapeutics, Inc. pays -- of its earnings as a dividend. Rigel Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Esperion Therapeutics, Inc. quarterly revenues are $168.4M, which are larger than Rigel Pharmaceuticals, Inc. quarterly revenues of $69.8M. Esperion Therapeutics, Inc.'s net income of $61.8M is lower than Rigel Pharmaceuticals, Inc.'s net income of $268.1M. Notably, Esperion Therapeutics, Inc.'s price-to-earnings ratio is -- while Rigel Pharmaceuticals, Inc.'s PE ratio is 1.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Esperion Therapeutics, Inc. is 1.35x versus 1.70x for Rigel Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.